MD
HealthcarePediatrix Medical Group, Inc. · Medical - Care Facilities · $2B
What is Pediatrix Medical Group, Inc.?
Pediatrix Medical Group is a U.S.-based physician services company focused on newborn, maternal-fetal, and pediatric subspecialty care. Operating across hospitals and outpatient settings, it connects specialized clinicians with patients at critical stages of early life.
Pediatrix generates revenue by staffing and managing physician practices within hospital systems, primarily in neonatal intensive care units and maternal-fetal medicine clinics. Affiliated subspecialists — including neonatologists, maternal-fetal medicine physicians, pediatric cardiologists, and other pediatric clinicians — deliver care under the Pediatrix umbrella. The company earns fees through patient care services, with reimbursement flowing from commercial insurers, Medicaid, and Medicare.
Founded in 1995 and headquartered in Sunrise, Florida, Pediatrix has built a national network of pediatric and maternal-fetal subspecialists.
- Neonatal care for premature and medically complex newborns
- Maternal-fetal medicine for high-risk pregnancies
- Pediatric cardiology for congenital and acquired heart conditions
- Pediatric intensive and hospital-based subspecialty care
- Pediatric surgical and ophthalmology subspecialty services
Is MD a Good Stock to Buy?
UQS Score rates MD as Good overall, reflecting a mixed but not alarming profile for a small-cap healthcare services company.
Valuation stands out as the most favorable pillar, suggesting the market may not be fully pricing in the company's underlying business relative to peers. Risk and Quality both register as Neutral, indicating the company is not exhibiting acute financial stress or dramatic operational deterioration.
Both the Moat and Growth pillars rate as Weak, pointing to limited competitive differentiation and constrained near-term expansion prospects — meaningful considerations for long-term holders.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does MD pay dividends?
No — Pediatrix Medical Group, Inc. does not currently pay a dividend.
Pediatrix Medical Group does not currently pay a dividend. For a company navigating reimbursement pressures and operational restructuring in physician services, retaining cash for balance sheet management and selective reinvestment is a common strategic posture. Income-focused investors should factor this into their overall assessment.
When does MD report earnings?
Pediatrix Medical Group reports earnings on a quarterly cadence, consistent with standard practice for U.S.-listed equities.
The company's recent results have reflected the broader pressures facing physician staffing businesses, including reimbursement headwinds and labor cost dynamics. Revenue trends and margin direction are best evaluated in the context of the full UQS pillar profile.
For the most recent quarter's results and guidance, visit Pediatrix Medical Group's investor relations page directly.
MD Price History
-28.5% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Pediatrix Medical Group, Inc.?
Based on Pediatrix Medical Group, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
MD Long-term Outlook
The Growth pillar rating of Weak suggests limited near-term revenue or earnings acceleration based on current fundamentals. However, the Attractive Valuation pillar indicates the stock may already reflect a cautious outlook, which could limit downside if operational trends stabilize. The Neutral Risk rating provides some reassurance that the balance sheet is not under acute pressure. Investors focused on a recovery thesis would want to monitor reimbursement trends and volume growth in neonatal and maternal-fetal care.
Growth drivers
- Expansion of hospital partnerships and affiliated physician networks
- Volume recovery in neonatal and high-risk pregnancy care settings
- Potential for operational efficiency gains across the physician services platform
Key risks
- Ongoing Medicaid and commercial reimbursement rate pressure
- Physician recruitment and retention challenges in subspecialty markets
- Weak Moat rating limits pricing power relative to hospital system counterparts
MD vs Peers
Pediatrix operates in a competitive healthcare services landscape alongside other specialty and post-acute care providers.
Select Medical focuses on long-term acute care hospitals and outpatient rehabilitation, serving a broader post-acute patient population than Pediatrix's neonatal and pediatric subspecialty niche.
Surgery Partners operates ambulatory surgical centers, competing for physician alignment and hospital partnerships but in a procedural rather than neonatal care context.
Addus delivers home-based personal care and hospice services, targeting a largely elderly population — a distinct patient demographic from Pediatrix's newborn and pediatric focus.
Frequently Asked Questions
What does Pediatrix Medical Group do?
Pediatrix Medical Group provides physician staffing and management services for neonatal, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care across U.S. hospitals and clinics. The company connects specialized clinicians with patients at critical early-life stages, earning revenue through patient care reimbursement.
Does MD pay dividends?
Pediatrix Medical Group does not currently pay a dividend. The company retains cash rather than distributing it to shareholders, which is common among healthcare services businesses managing reimbursement pressures and operational costs.
When does MD report earnings?
Pediatrix reports on a standard quarterly schedule. For exact dates and the most recent results, check the investor relations section of the company's official website, as our data source does not provide specific upcoming earnings dates.
Is MD a good stock to buy?
UQS Score rates MD as Good overall. The Valuation pillar is Attractive, and Risk and Quality are both Neutral. However, Moat and Growth both rate as Weak, which tempers the overall picture. The full pillar breakdown is available to UQS Pro members.
Is MD overvalued?
Based on the UQS Valuation pillar, MD currently rates as Attractive, suggesting the stock may be trading at a discount relative to its fundamentals compared to sector peers. This does not guarantee price appreciation but indicates the market is pricing in a cautious outlook.
How does MD compare to its competitors?
Pediatrix occupies a specialized niche in neonatal and pediatric subspecialty care, which differentiates it from broader post-acute or surgical services peers like Select Medical and Surgery Partners. Its focus is narrower, which can be both a competitive strength and a constraint on growth.
What is MD's market cap bracket?
Pediatrix Medical Group is classified as a small-cap company. This places it in a segment of the market that can carry higher volatility and liquidity considerations compared to large- or mega-cap healthcare peers.
Who founded Pediatrix Medical Group?
Pediatrix Medical Group was founded in 1995. For detailed founding history and leadership background, the company's official investor relations and about pages provide publicly available information.
Is MD a long-term quality stock?
As a long-term quality indicator, MD's UQS profile is mixed. The Neutral Quality and Risk pillars suggest the business is not in distress, but Weak Moat and Growth ratings indicate limited durable competitive advantage and expansion momentum — factors that matter significantly over a long investment horizon.
What is the main competitive advantage of Pediatrix Medical Group?
Pediatrix's primary advantage lies in its established network of affiliated subspecialists and its deep integration within hospital neonatal and maternal-fetal units. However, the UQS Moat pillar rates as Weak, suggesting this advantage may not be strongly defensible against competitive or reimbursement pressures.
What sector does MD belong to?
Pediatrix Medical Group operates in the Healthcare sector, specifically within physician staffing and subspecialty care services. It is part of a segment that is sensitive to government reimbursement policy, labor market dynamics, and hospital system relationships.
Is MD a growth stock or value stock?
Based on UQS pillar labels, MD leans toward value territory — the Valuation pillar is Attractive while the Growth pillar is Weak. This profile is more consistent with a value or turnaround framing than a high-growth investment thesis.
Unlock Full MD Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete UQS pillar score breakdown for MD
- ✓Access detailed financial metrics and trend data
- ✓Compare MD against sector peers on every pillar
- ✓Screen small-cap healthcare stocks by quality and valuation
- ✓Get the full analyst-style view available to Pro members
Pro Analysis
MD — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 20, 2026 | 52.7 | 59.3 | 36.0 | 36.7 | 48.1 | 95.7 | -0.1 |
| May 18, 2026 | 52.8 | 59.3 | 36.0 | 36.7 | 48.1 | 96.4 | +0.1 |
| May 15, 2026 | 52.7 | 59.3 | 36.0 | 36.7 | 48.1 | 95.6 | +0.1 |
| May 14, 2026 | 52.6 | 59.3 | 36.0 | 36.7 | 48.1 | 94.9 | 0.0 |
| May 12, 2026 | 52.6 | 59.3 | 36.0 | 36.7 | 48.1 | 94.8 | -0.7 |
| May 7, 2026 | 53.3 | 57.9 | 36.0 | 35.1 | 54.1 | 98.1 | -0.1 |
| Apr 26, 2026 | 53.4 | 57.9 | 36.0 | 35.1 | 54.1 | 98.5 | +0.1 |
| Apr 23, 2026 | 53.3 | 57.9 | 36.0 | 35.1 | 54.1 | 98.0 | 0.0 |
| Apr 19, 2026 | 53.3 | 57.9 | 36.0 | 35.0 | 54.1 | 98.0 | -0.2 |
| Apr 18, 2026 | 53.5 | 57.9 | 36.0 | 35.0 | 54.1 | 99.2 | -0.1 |
MD — Pillar Breakdown
Quality
— 59.3/100 (25%)Pediatrix Medical Group, Inc. shows solid profitability with healthy returns on capital and reasonable margins.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 36.7/100 (20%)Pediatrix Medical Group, Inc. shows steady but unspectacular growth, typical for mature companies.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 48.1/100 (15%)Pediatrix Medical Group, Inc. has some risk factors including moderate leverage or solvency concerns.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 96.3/100 (15%)Pediatrix Medical Group, Inc. appears attractively valued relative to its earnings, cash flows, and sector peers.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
P/E relative to earnings growth — lower is more attractive.
Enterprise value multiple relative to sector median.
Moat
— 36/100 (25%)Pediatrix Medical Group, Inc. possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for MD.
Score Composition
Financial Data
More Stock Analysis
How is the MD UQS Score Calculated?
The UQS (Unified Quality Score) for Pediatrix Medical Group, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Pediatrix Medical Group, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Pediatrix Medical Group, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.